AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Invitrogen consolidated 64% within its base, but has worked its way back up. After swimming above and below its 50- and 200-day moving averages from mid-March to November, the stock has been traveling above both lines since the beginning of December. It's 13% off its high.
The Carlsbad, Calif.-based firm makes gene research tools for corporate, academic and government fields.
Earnings growth has picked up in the past two quarters, from 13% to
58% to 100%. Analysts expect earnings to rise 100% in both of the next two quarters, First Call says.
Sales growth has been 17% or higher for at least 13 quarters. Last quarter, revenue rose 102% to $48 million.
...